Global Leprosy Treatment Market
Global Leprosy Treatment Market

Leprosy Treatment Comprehensive Study by Type (Borderline Tuberculoid, Tuberculoid, Borderline, Histoid, Others), Drug Type (Antibacterial, Leprostatics, Antitubercular, Others), Leprosy Type (Multibacillary Leprosy, Paucibacillary Leprosy), End-Use (Hospitals, Clinics) Players and Region - Global Market Outlook to 2026

Leprosy Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 243 Pages 171 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Leprosy Treatment Market Overview:
Leprosy is a disease caused by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis, which causes granulomas in the nerves, respiratory tract, and other organs. Granulomas can cause a loss of pain perception, particularly in the extremities, such as the finger tips. The nerves, skin, eyes, mucosa (of the mouth, nose, and pharynx), kidneys, testes, reticulo-endothelial system, and voluntary smooth muscles of the human body are the most affected. Leprosy symptoms are easy to recognize. Skin lesions with no feeling, as well as thickened or damaged nerves, are examples. Paucibacillary leprosy and multibacillary leprosy are the two types of leprosy. Some of the players profiled in the study are Glaxo Smithcline (United Kingdom), Cadila Pharmaceuticals (India), Acme Pharmaceuticals (India), Indian Drugs and Pharmaceuticals (India), Novartis International AG (Switzerland), Astra Zeneca (United Kingdom), Lark Laboratories Ltd (India), GlaxoSmithKline (United Kingdom), Sanofi (France) and Apotex (Canada).

On the basis of geography, the market of Leprosy Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Antibacterial will boost the Leprosy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Leprosy Type, the sub-segment i.e. Multibacillary Leprosy will boost the Leprosy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Use, the sub-segment i.e. Hospitals will boost the Leprosy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Favorable Government Initiatives
  • Availability of Favorable Reimbursement Policies for High-Cost Therapies

Influencing Trend
  • Rising Patient Pool of Leprosy in Asia-Pacific

Restraints
  • Low Health Care Expenditure and Least Availability of Medical Facilities for Proper Diagnosis of Leprosy Treatment

Opportunities
  • New Treatment Options Available for Leprosy Treatment



According to WHO - The guidelines recommend a 3-drug regimen of rifampicin, dapsone and clofazimine for all leprosy patients, with a duration of treatment of 6 months for PB leprosy and 12 months for MB leprosy.

Target Audience:
Manufacturers of Leprosy Drug, Suppliers of Leprosy Drug, Wholesalers, Distributors and Retailers of Leprosy Drug, Healthcare Industry, Pharmaceutical Industry and Regulatory Bodies

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Leprosy Treatment market on the basis of product [Borderline Tuberculoid, Tuberculoid, Borderline, Histoid and Others] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Leprosy Treatment market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Leprosy Treatment industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Macleods Pharmaceuticals (India) and Systopic Laboratories (India).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Leprosy Treatment market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Borderline Tuberculoid
  • Tuberculoid
  • Borderline
  • Histoid
  • Others
By Drug Type
  • Antibacterial
  • Leprostatics
  • Antitubercular
  • Others

By Leprosy Type
  • Multibacillary Leprosy
  • Paucibacillary Leprosy

By End-Use
  • Hospitals
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Favorable Government Initiatives
      • 3.2.2. Availability of Favorable Reimbursement Policies for High-Cost Therapies
    • 3.3. Market Trends
      • 3.3.1. Rising Patient Pool of Leprosy in Asia-Pacific
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Leprosy Treatment, by Type, Drug Type, Leprosy Type, End-Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Leprosy Treatment (Value)
      • 5.2.1. Global Leprosy Treatment by: Type (Value)
        • 5.2.1.1. Borderline Tuberculoid
        • 5.2.1.2. Tuberculoid
        • 5.2.1.3. Borderline
        • 5.2.1.4. Histoid
        • 5.2.1.5. Others
      • 5.2.2. Global Leprosy Treatment by: Drug Type (Value)
        • 5.2.2.1. Antibacterial
        • 5.2.2.2. Leprostatics
        • 5.2.2.3. Antitubercular
        • 5.2.2.4. Others
      • 5.2.3. Global Leprosy Treatment by: Leprosy Type (Value)
        • 5.2.3.1. Multibacillary Leprosy
        • 5.2.3.2. Paucibacillary Leprosy
      • 5.2.4. Global Leprosy Treatment by: End-Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
      • 5.2.5. Global Leprosy Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Leprosy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Glaxo Smithcline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cadila Pharmaceuticals (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Acme Pharmaceuticals (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Indian Drugs and Pharmaceuticals (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis International AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Astra Zeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lark Laboratories Ltd (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Apotex (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Leprosy Treatment Sale, by Type, Drug Type, Leprosy Type, End-Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Leprosy Treatment (Value)
      • 7.2.1. Global Leprosy Treatment by: Type (Value)
        • 7.2.1.1. Borderline Tuberculoid
        • 7.2.1.2. Tuberculoid
        • 7.2.1.3. Borderline
        • 7.2.1.4. Histoid
        • 7.2.1.5. Others
      • 7.2.2. Global Leprosy Treatment by: Drug Type (Value)
        • 7.2.2.1. Antibacterial
        • 7.2.2.2. Leprostatics
        • 7.2.2.3. Antitubercular
        • 7.2.2.4. Others
      • 7.2.3. Global Leprosy Treatment by: Leprosy Type (Value)
        • 7.2.3.1. Multibacillary Leprosy
        • 7.2.3.2. Paucibacillary Leprosy
      • 7.2.4. Global Leprosy Treatment by: End-Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
      • 7.2.5. Global Leprosy Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Leprosy Treatment: by Type(USD Million)
  • Table 2. Leprosy Treatment Borderline Tuberculoid , by Region USD Million (2015-2020)
  • Table 3. Leprosy Treatment Tuberculoid , by Region USD Million (2015-2020)
  • Table 4. Leprosy Treatment Borderline , by Region USD Million (2015-2020)
  • Table 5. Leprosy Treatment Histoid , by Region USD Million (2015-2020)
  • Table 6. Leprosy Treatment Others , by Region USD Million (2015-2020)
  • Table 7. Leprosy Treatment: by Drug Type(USD Million)
  • Table 8. Leprosy Treatment Antibacterial , by Region USD Million (2015-2020)
  • Table 9. Leprosy Treatment Leprostatics , by Region USD Million (2015-2020)
  • Table 10. Leprosy Treatment Antitubercular , by Region USD Million (2015-2020)
  • Table 11. Leprosy Treatment Others , by Region USD Million (2015-2020)
  • Table 12. Leprosy Treatment: by Leprosy Type(USD Million)
  • Table 13. Leprosy Treatment Multibacillary Leprosy , by Region USD Million (2015-2020)
  • Table 14. Leprosy Treatment Paucibacillary Leprosy , by Region USD Million (2015-2020)
  • Table 15. Leprosy Treatment: by End-Use(USD Million)
  • Table 16. Leprosy Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 17. Leprosy Treatment Clinics , by Region USD Million (2015-2020)
  • Table 18. South America Leprosy Treatment, by Country USD Million (2015-2020)
  • Table 19. South America Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 20. South America Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 21. South America Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 22. South America Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 23. Brazil Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 24. Brazil Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 25. Brazil Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 26. Brazil Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 27. Argentina Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 28. Argentina Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 29. Argentina Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 30. Argentina Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 31. Rest of South America Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 33. Rest of South America Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 34. Rest of South America Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 35. Asia Pacific Leprosy Treatment, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 38. Asia Pacific Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 39. Asia Pacific Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 40. China Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 41. China Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 42. China Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 43. China Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 44. Japan Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 45. Japan Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 46. Japan Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 47. Japan Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 48. India Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 49. India Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 50. India Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 51. India Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 52. South Korea Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 53. South Korea Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 54. South Korea Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 55. South Korea Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 56. Taiwan Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 57. Taiwan Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 58. Taiwan Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 59. Taiwan Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 60. Australia Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 61. Australia Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 62. Australia Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 63. Australia Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 68. Europe Leprosy Treatment, by Country USD Million (2015-2020)
  • Table 69. Europe Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 70. Europe Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 71. Europe Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 72. Europe Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 73. Germany Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 74. Germany Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 75. Germany Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 76. Germany Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 77. France Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 78. France Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 79. France Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 80. France Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 81. Italy Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 82. Italy Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 83. Italy Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 84. Italy Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 85. United Kingdom Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 87. United Kingdom Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 88. United Kingdom Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 89. Netherlands Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 90. Netherlands Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 91. Netherlands Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 92. Netherlands Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 93. Rest of Europe Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 95. Rest of Europe Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 96. Rest of Europe Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 97. MEA Leprosy Treatment, by Country USD Million (2015-2020)
  • Table 98. MEA Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 99. MEA Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 100. MEA Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 101. MEA Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 102. Middle East Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 103. Middle East Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 104. Middle East Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 105. Middle East Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 106. Africa Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 107. Africa Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 108. Africa Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 109. Africa Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 110. North America Leprosy Treatment, by Country USD Million (2015-2020)
  • Table 111. North America Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 112. North America Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 113. North America Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 114. North America Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 115. United States Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 116. United States Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 117. United States Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 118. United States Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 119. Canada Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 120. Canada Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 121. Canada Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 122. Canada Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 123. Mexico Leprosy Treatment, by Type USD Million (2015-2020)
  • Table 124. Mexico Leprosy Treatment, by Drug Type USD Million (2015-2020)
  • Table 125. Mexico Leprosy Treatment, by Leprosy Type USD Million (2015-2020)
  • Table 126. Mexico Leprosy Treatment, by End-Use USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Leprosy Treatment: by Type(USD Million)
  • Table 138. Leprosy Treatment Borderline Tuberculoid , by Region USD Million (2021-2026)
  • Table 139. Leprosy Treatment Tuberculoid , by Region USD Million (2021-2026)
  • Table 140. Leprosy Treatment Borderline , by Region USD Million (2021-2026)
  • Table 141. Leprosy Treatment Histoid , by Region USD Million (2021-2026)
  • Table 142. Leprosy Treatment Others , by Region USD Million (2021-2026)
  • Table 143. Leprosy Treatment: by Drug Type(USD Million)
  • Table 144. Leprosy Treatment Antibacterial , by Region USD Million (2021-2026)
  • Table 145. Leprosy Treatment Leprostatics , by Region USD Million (2021-2026)
  • Table 146. Leprosy Treatment Antitubercular , by Region USD Million (2021-2026)
  • Table 147. Leprosy Treatment Others , by Region USD Million (2021-2026)
  • Table 148. Leprosy Treatment: by Leprosy Type(USD Million)
  • Table 149. Leprosy Treatment Multibacillary Leprosy , by Region USD Million (2021-2026)
  • Table 150. Leprosy Treatment Paucibacillary Leprosy , by Region USD Million (2021-2026)
  • Table 151. Leprosy Treatment: by End-Use(USD Million)
  • Table 152. Leprosy Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 153. Leprosy Treatment Clinics , by Region USD Million (2021-2026)
  • Table 154. South America Leprosy Treatment, by Country USD Million (2021-2026)
  • Table 155. South America Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 156. South America Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 157. South America Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 158. South America Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 159. Brazil Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 160. Brazil Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 161. Brazil Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 162. Brazil Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 163. Argentina Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 164. Argentina Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 165. Argentina Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 166. Argentina Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 167. Rest of South America Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 168. Rest of South America Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 169. Rest of South America Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 170. Rest of South America Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 171. Asia Pacific Leprosy Treatment, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 173. Asia Pacific Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 174. Asia Pacific Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 175. Asia Pacific Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 176. China Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 177. China Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 178. China Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 179. China Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 180. Japan Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 181. Japan Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 182. Japan Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 183. Japan Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 184. India Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 185. India Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 186. India Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 187. India Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 188. South Korea Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 189. South Korea Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 190. South Korea Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 191. South Korea Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 192. Taiwan Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 193. Taiwan Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 194. Taiwan Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 195. Taiwan Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 196. Australia Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 197. Australia Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 198. Australia Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 199. Australia Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 204. Europe Leprosy Treatment, by Country USD Million (2021-2026)
  • Table 205. Europe Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 206. Europe Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 207. Europe Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 208. Europe Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 209. Germany Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 210. Germany Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 211. Germany Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 212. Germany Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 213. France Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 214. France Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 215. France Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 216. France Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 217. Italy Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 218. Italy Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 219. Italy Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 220. Italy Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 221. United Kingdom Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 222. United Kingdom Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 223. United Kingdom Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 224. United Kingdom Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 225. Netherlands Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 226. Netherlands Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 227. Netherlands Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 228. Netherlands Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 229. Rest of Europe Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 230. Rest of Europe Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 231. Rest of Europe Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 232. Rest of Europe Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 233. MEA Leprosy Treatment, by Country USD Million (2021-2026)
  • Table 234. MEA Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 235. MEA Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 236. MEA Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 237. MEA Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 238. Middle East Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 239. Middle East Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 240. Middle East Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 241. Middle East Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 242. Africa Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 243. Africa Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 244. Africa Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 245. Africa Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 246. North America Leprosy Treatment, by Country USD Million (2021-2026)
  • Table 247. North America Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 248. North America Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 249. North America Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 250. North America Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 251. United States Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 252. United States Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 253. United States Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 254. United States Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 255. Canada Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 256. Canada Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 257. Canada Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 258. Canada Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 259. Mexico Leprosy Treatment, by Type USD Million (2021-2026)
  • Table 260. Mexico Leprosy Treatment, by Drug Type USD Million (2021-2026)
  • Table 261. Mexico Leprosy Treatment, by Leprosy Type USD Million (2021-2026)
  • Table 262. Mexico Leprosy Treatment, by End-Use USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Leprosy Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Leprosy Treatment: by Drug Type USD Million (2015-2020)
  • Figure 6. Global Leprosy Treatment: by Leprosy Type USD Million (2015-2020)
  • Figure 7. Global Leprosy Treatment: by End-Use USD Million (2015-2020)
  • Figure 8. South America Leprosy Treatment Share (%), by Country
  • Figure 9. Asia Pacific Leprosy Treatment Share (%), by Country
  • Figure 10. Europe Leprosy Treatment Share (%), by Country
  • Figure 11. MEA Leprosy Treatment Share (%), by Country
  • Figure 12. North America Leprosy Treatment Share (%), by Country
  • Figure 13. Global Leprosy Treatment share by Players 2020 (%)
  • Figure 14. Global Leprosy Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Leprosy Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Glaxo Smithcline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Glaxo Smithcline (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 20. Cadila Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 21. Acme Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 22. Acme Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 23. Indian Drugs and Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 24. Indian Drugs and Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 25. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. Astra Zeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Astra Zeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Lark Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 30. Lark Laboratories Ltd (India) Revenue: by Geography 2020
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2020
  • Figure 35. Apotex (Canada) Revenue, Net Income and Gross profit
  • Figure 36. Apotex (Canada) Revenue: by Geography 2020
  • Figure 37. Global Leprosy Treatment: by Type USD Million (2021-2026)
  • Figure 38. Global Leprosy Treatment: by Drug Type USD Million (2021-2026)
  • Figure 39. Global Leprosy Treatment: by Leprosy Type USD Million (2021-2026)
  • Figure 40. Global Leprosy Treatment: by End-Use USD Million (2021-2026)
  • Figure 41. South America Leprosy Treatment Share (%), by Country
  • Figure 42. Asia Pacific Leprosy Treatment Share (%), by Country
  • Figure 43. Europe Leprosy Treatment Share (%), by Country
  • Figure 44. MEA Leprosy Treatment Share (%), by Country
  • Figure 45. North America Leprosy Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Glaxo Smithcline (United Kingdom)
  • Cadila Pharmaceuticals (India)
  • Acme Pharmaceuticals (India)
  • Indian Drugs and Pharmaceuticals (India)
  • Novartis International AG (Switzerland)
  • Astra Zeneca (United Kingdom)
  • Lark Laboratories Ltd (India)
  • GlaxoSmithKline (United Kingdom)
  • Sanofi (France)
  • Apotex (Canada)
Additional players considered in the study are as follows:
Macleods Pharmaceuticals (India) , Systopic Laboratories (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation